Cover Image

WHO efforts to promote reporting of adverse events and global learning

<p>Despite the importance of reporting systems to learn about the casual chain and consequences of patient safety incidents, this is an area that requires of further conceptual and technical developments to conduce reporting to effective learning. The World Health Organization, through its Pat...

Full description

Saved in:

Bibliographic Details
Main Authors:	Itziar Larizgoitia (Author), Marie-Charlotte Bouesseau (Author), Edward Kelley (Author)
Format:	Book
Published:	SAGE Publishing, 2013-12-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Las palabras y las cosas
by: Larizgoitia Itziar
Published: (2003)

Las palabras y las cosas Words and things
by: Itziar Larizgoitia
Published: (2003)

<title language="eng">Patient safety: a human factor approach
by: Itziar Larizgoitia
Published: (2012)

Indications and adverse events of teriparatide: based on FDA adverse event reporting system (FAERS)
by: Ming-Tao Wen, et al.
Published: (2024)

Safer primary care for all: a global imperative
by: Aziz Sheikh, et al.
Published: (2013)

Vonoprazan-associated infection: an analysis of the Japanese Adverse Drug Event Report and the FDA Adverse Event Reporting System
by: Mengling Ouyang, et al.
Published: (2024)

NURSES' KNOWLEDGE ABOUT ADVERSE EVENTS AND THE CHALLENGES OF REPORTING THESE EVENTS
by: Jamilly Santos Araujo, et al.
Published: (2016)

Adverse Events Related to Off-Label Drugs Using Spontaneous Adverse Event Reporting Systems
by: Han N, et al.
Published: (2021)

Adverse events associated with herbal medicine products reported in the Korea Adverse Event Reporting System from 2012 to 2021
by: Yujin Choi, et al.
Published: (2024)

Patterns of use and adverse events reported among persons who regularly inject buprenorphine: a systematic review
by: Nikki Bozinoff, et al.
Published: (2022)

Serious Cardiovascular Adverse Events Reported with Intravenous Sedatives: A Retrospective Analysis of the MedWatch Adverse Event Reporting System
by: Matthew S. Duprey, et al.
Published: (2019)

ANALYSIS OF ADVERSE EVENT REPORTING AT ACCREDITED HOSPITALS
by: Tatiana Paula Miguelaci Ferezin, et al.
Published: (2017)

Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system
by: Yamin Shu, et al.
Published: (2022)

Musculoskeletal Adverse Events Associated with PCSK9 Inhibitors: Disproportionality Analysis of the FDA Adverse Event Reporting System
by: Lingqing Ding, et al.
Published: (2022)

Adverse events related to neuromuscular blocking agents: a disproportionality analysis of the FDA adverse event reporting system
by: Liangxia Li, et al.
Published: (2024)

Neurological adverse events associated with oxaliplatin: A pharmacovigilance analysis based on FDA adverse event reporting system
by: Xianglin Pan, et al.
Published: (2024)

Postmarketing Surveillance of Full Spectrum Hemp Extract CBD Products: Reported Adverse Events and Serious Adverse Events
by: Colleen M. Kingsbury, et al.
Published: (2024)

Psoriasis adverse events and associated medications as reported in the US Food and Drug Administration's Adverse Event Reporting System from 2016 to 2021
by: Christine Learned, BA, et al.
Published: (2022)

Correction: Patterns of use and adverse events reported among persons who regularly inject buprenorphine: a systematic review
by: Nikki Bozinoff, et al.
Published: (2022)

Characteristics of pediatric adverse drug reaction reports in the Japanese Adverse Drug Event Report Database
by: Aoi Noda, et al.
Published: (2020)

Comparing the difference of adverse events with HER2 inhibitors: a study of the FDA adverse event reporting system (FAERS)
by: Yiwen Bao, et al.
Published: (2024)

Adverse events in different administration routes of semaglutide: a pharmacovigilance study based on the FDA adverse event reporting system
by: Kaibin Niu, et al.
Published: (2024)

META-INSTI: metabolic adverse events following integrase strand transfer inhibitor administration in spontaneous adverse event reports
by: Milena M Murray, et al.
Published: (2023)

Indication and adverse event profiles of denosumab and zoledronic acid: based on U.S. FDA adverse event reporting system (FAERS)
by: Si Su, et al.
Published: (2023)

Neuropsychiatric Adverse Events with Monoclonal Antibodies Approved for Multiple Myeloma: An Analysis from the FDA Adverse Event Reporting System
by: Giuseppe Cicala, et al.
Published: (2024)

Vemurafenib and cutaneous adverse events - report of five cases
by: Giselle de Barros Silva, et al.
Published: (2015)

The practice of reporting adverse events in a teaching hospital
by: Andréia Guerra Siman, et al.
Published: (2017)

Supportive Care-A Missing Piece in the Current Global Efforts of Promoting Respectful Maternity Care
by: Waqas Hameed, et al.
Published: (2024)

A disproportionality analysis of FDA adverse event reporting system (FAERS) events for ticagrelor
by: Yunyan Pan, et al.
Published: (2024)

Identification of small cell lung cancer patients who are at risk of developing common serious adverse event groups with machine learning
by: Linda Wanika, et al.
Published: (2023)

Analysis of Adverse Events of Cholinesterase Inhibitors and NMDA Receptor Antagonists on Arrhythmias Using the Japanese Adverse Drug Event Report Database
by: Shotaro Kobayashi, et al.
Published: (2023)

Adverse event profiles of dipeptidyl peptidase-4 inhibitors: data mining of the public version of the FDA adverse event reporting system
by: Jing Huang, et al.
Published: (2020)

Ocular adverse events associated with anti-VEGF therapy: A pharmacovigilance study of the FDA adverse event reporting system (FAERS)
by: Pan Ma, et al.
Published: (2022)

Adverse drug events in the prevention and treatment of COVID-19: A data mining study on the FDA adverse event reporting system
by: Qiang Guo, et al.
Published: (2022)

Neurological Adverse Events Associated With Esketamine: A Disproportionality Analysis for Signal Detection Leveraging the FDA Adverse Event Reporting System
by: Haoning Guo, et al.
Published: (2022)

Safety assessment of sapropterin dihydrochloride: real-world adverse event analysis based on the FDA adverse event reporting system (FAERS)
by: Jiahong Zhong, et al.
Published: (2024)

Adverse event profile of lorazepam: a real-world pharmacovigilance study using the FDA adverse event reporting system database
by: Zhengkang Su, et al.
Published: (2024)

Adverse event profiles of CDK4/6 inhibitors: data mining and disproportionality analysis of the FDA adverse event reporting system
by: Jun Shen, et al.
Published: (2024)

Adverse events associated with molnupiravir: a real-world disproportionality analysis in food and drug administration adverse event reporting system
by: Yankun Liang, et al.
Published: (2023)

Analysis of fall-related adverse events among older adults using the Japanese Adverse Drug Event Report (JADER) database
by: Haruna Hatahira, et al.
Published: (2018)